In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...

Yet only small percentages of patients with new diagnoses sought follow-up care, started or completed treatment, or attained ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...